SCHEMBL15056293

SCHEMBL15056293

Cc1cccc(COC(=O)N2C=Cc3ccccc3C2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.41
PTGDR2 Q9Y5Y4 2/20 0.38
MEN1 O00255 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
KMT2A Q03164 1/20 0.36
GRM5 P41594 8/20 0.34
CYP1A2 P05177 3/20 0.34
GRM1 Q13255 2/20 0.34
CYP3A4 P08684 2/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
HDAC3 O15379 1/20 0.34
GABRA1 P14867 3/20 0.34
GABRG2 P18507 3/20 0.34
GABRB3 P28472 3/20 0.34
GABRA5 P31644 3/20 0.34
GABRA3 P34903 3/20 0.34
GABRA2 P47869 3/20 0.34
CACNA1C Q13936 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL325217 0.83 HDAC3 (0.33) GRM5CYP1A2GRM1CYP3A4HDAC3
SCHEMBL15057230 0.82 NPC1 (0.43) PTGDR2CYP1A2CYP3A4PRMT5WDR77
SCHEMBL324968 0.82 ALDH1A1 (0.44) PTGDR2MEN1KMT2A
SCHEMBL15056964 0.81 HDAC3 (0.41) MEN1KMT2AHDAC3
SCHEMBL29493251 0.81 HDAC3 (0.41) MEN1KMT2AHDAC3
SCHEMBL324429 0.81 HDAC3 (0.36) MEN1KMT2ACYP3A4HDAC3
SCHEMBL324037 0.81 MAPT (0.40) GABRA1GABRA5
SCHEMBL324577 0.81 RAB9A (0.35) MEN1KMT2AGRM5HDAC3GABRA1
SCHEMBL14893014 0.80 ALDH1A1 (0.36) CYP1A2CYP3A4HDAC3
SCHEMBL324346 0.80 P2RX4 (0.47) MEN1KMT2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255090-B2 Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-09 US disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 EP disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 DPP4 4123/4885PTGDR2 3/4885MEN1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.